Figure 2
From: Effects of GRK5 and ADRB1 polymorphisms influence on systolic heart failure
GRK5 and ADRB1 polymorphisms influence on beta-blocker treatment with SHF. Note: CI denotes confidence interval. Advantage of beta-blocker indicated that the gene polymorphisms could decrease the risk of SHF morbidity after β-blocker therapy; Disadvantage of beta-blocker indicated that the gene polymorphisms could not reduce the risk of SHF morbidity after β-blocker therapy.